Generalizability of HFrEF trials 49 Supplementary table 5. Number and percentage of patients who received <50% or >= 50% target doses of heart failure medications: comparing target doses between the overall study period and after restricting to only time period coinciding with the two largest trials Values are expressed as number (%) a- time period which coincides with the conduct of the two largest trials in this study ACE, angiotensin- converting enzyme inhibitor; ARB, angiotensin-II receptor blocker RCT SwedeHF registry all (2001 - 2016) 2005-2009a n 16922 40230 (100%) 15025 (37%) Target doses of heart failure medications– no (%) ACEI >0 - <50% 4313 33% 8455 28% 2399 23% >=50% 8567 67% 22056 72% 7817 77% ARB >0 - <50% 1181 61% 5150 48% 1620 54% >=50% 761 39% 5537 52% 1386 46% ACEI/ARB >0 - <50% 5417 37% 13196 33% 3814 30% >=50% 9242 63% 27231 67% 9025 70% Beta-blocker >0 - <50% 7096 50% 15966 39% 5039 39% >=50% 6968 50% 25499 61% 7995 61% 2.1
RkJQdWJsaXNoZXIy MjY0ODMw